Patient Education Programme for Multiple Sclerosis (MS) Immunotherapy
Effectiveness of a patient education programme on immunotherapy in multiple sclerosis - a multicentre controlled trial
What it found
A paper reports the results; we have not read it yet. See Papers below.
What it measured
Main measures
Informed choice (IC) about initiation or continuation of immunotherapies after 6 months of follow-up using an adaptation of the Multidimensional Measure of Informed Choice (MMIC), comprising appropriate disease-related risk-knowledge and consistency between attitude and decision
Other measures (1)
1. Autonomy preference assessed in the first week of rehabilitation (before the intervention) and after 6 months using a previously used scale based on the Control Preference Scale (CPS) 2. Risk knowledge after 6 months 3. Decision conflict and satisfaction with the decision assessed after 6 months using the Decisional Conflict Scale (DCS) 4. Anxiety and depression assessed in the third or fourth
FatigueMood and sleepQuality of life (reported by participants)Safety
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
Inclusion: 1. Possible or definite MS following revised McDonald criteria 2. Attending rehabilitation programme in participating rehab centres during study period 3. Aged 18 - 65 years, either sex Exclusion: 1. Major cognitive deficit 2. Inability to independently fill in questionnaires, e.g., due to ataxia
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Not provided at time of registration
Papers
Results
results
Loading reviews and guidelines…
History
Started
Apr 2010
Finished
Sept 2011